CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. A live webcast will be... Read More

Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101 Preclinical ESCAPE Data Establish Proof-of-concept for Non-genotoxic, Antibody-based Conditioning and Engraftment in Non-human Primates Clinical Data from Phase 1/2 BEAM-201 Trial Demonstrate Therapeutic Potential of First Quadruplex-edited Allogeneic CAR-T Cell Therapy Beam to Host Investor Event on... Read More

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expected in 2025 Ended Third Quarter... Read More

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66 th... Read More

U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Submitted for Presentation at the American Society of Hematology (ASH) Annual... Read More

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company... Read More

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a... Read More

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines in a poster presentation at the European Hematology Association (EHA) Hybrid... Read More

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET in New York City. A live webcast will be available in the... Read More

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA)... Read More

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will... Read More

Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter... Read More

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with alpha-1... Read More

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference, emerging genetic therapy approaches corporate panel discussion on Wednesday, March 6, 2024 at 12:50 p.m. ET... Read More

Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation for BEAM-302 in Alpha-1 Antitrypsin Deficiency on Track for First Half of 2024 Pending European Clinical Trial Application (CTA) Acceptance Ended Fourth Quarter 2023 with $1.2 Billion in Cash, Cash Equivalents and Marketable... Read More

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET in New York. A live webcast will be available in the investor... Read More

First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024 Investigational New Drug (IND) Application for... Read More

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company's website at... Read More

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently... Read More

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, plans to participate in a fireside chat during the 2023 Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 4:30 p.m. GMT in London. A live webcast will be available in the... Read More

Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development-Stage Payments GMP Operations Initiated at Beam's North Carolina Manufacturing Facility... Read More

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Eli Lilly and Company (Lilly) has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics, Inc. (Verve), including Beam’s opt-in rights to co-develop and co-commercialize... Read More

Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year Company Plans to Submit U.S. Investigational New Drug (IND) Application for BEAM-301 in the First Half of 2024 CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new... Read More

Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to explore partnership opportunities for continued development of select programs Anticipated cost savings, which includes an approximately 20% reduction in workforce, expected to extend the company’s cash runway into 2026 CAMBRIDGE,... Read More

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to directly correct the PiZ mutation, the primary disease-causing mutation associated with severe alpha-1 antitrypsin deficiency (AATD). The data... Read More

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. BEAM-201 is being evaluated in a Phase 1/2 clinical study for the treatment of relapsed/refractory T-cell... Read More

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences: Citi’s 18 th Annual BioPharma Conference 2023 on Thursday, September 7, 2023 at 8:50 a.m. ET in Boston; 2023 Wells Fargo... Read More

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Company to Accelerate Development of BEAM-302 for Treatment of AATD; Program Now Expected to be First In Vivo Liver Regulatory Filing in First Quarter of... Read More

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following May investor conferences: Barclays Virtual Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023 at 11:05 a.m. ET; Stifel 2023 Tailoring Genes: Virtual... Read More

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2023 Global Healthcare Conference on Wednesday, May 17, 2023, at 11:00 a.m. ET in NYC. A live webcast will be... Read More

Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-101 for Patients with Sickle Cell Disease Twenty-Year Industry Veteran, Gopi Shanker, Ph.D., Appointed as Chief Scientific Officer Well-Capitalized with $1.1... Read More

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Guggenheim 2023 Genomic Medicines and Rare Disease Day on Monday, April 3, 2023 at 10:10 a.m. ET in NYC. A live webcast will be available in the... Read More

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO). Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities. Dr.... Read More

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, will participate in a fireside chat during the Barclays 2023 Global Healthcare Conference on Thursday, March 16, 2023 at 8:30 a.m. ET in Miami, FL. A live webcast will be available in... Read More

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a panel titled, “Gene Editing Corporate Panel” during the 43 rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET in Boston. A live webcast... Read More

Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines North Carolina Manufacturing Facility Open and Operational, Expected to Commence cGMP Operations in Late 2023 Ended Fourth Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities... Read More

CAMBRIDGE, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference on Tuesday, February 14, 2023, at 8:40 a.m. ET. A live webcast will be available in the investor... Read More

BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 North Carolina Manufacturing Facility Expected to Initiate GMP Operations in Late 2023... Read More

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, 2023 at 11:15 a.m. PT in San Francisco. The live webcast will be available in the investor section of the company's website at... Read More